NASDAQ$ELVN
Enliven Therapeutics Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Reported financial results for the fourth quarter and full year ended December 31, 2023, and provided updated guidance on parallel lead product candidates and highlighted pipeline progress.
Enliven Therapeutics reported a net loss of $19.4 million for the fourth quarter of 2023, with R&D expenses at $17.9 million and G&A expenses at $4.8 million. The company closed the year with $253.1 million in cash, cash equivalents, and marketable securities, expected to provide cash runway into early 2026. Initial proof of concept data from Phase 1a trial evaluating ELVN-001 in adults with chronic myeloid leukemia (CML) is expected in the second quarter of 2024.
- Phase 1 trial of ELVN-001 is on track, with initial proof of concept data expected in Q2 2024.
- FDA accepted IND application for ELVN-002 to evaluate combination therapy in HER2+ cancers, with first patient dosing expected by mid-2024.
- R&D expenses were $17.9 million for Q4 2023, compared to $8.2 million for Q4 2022.
- Cash, cash equivalents, and marketable securities totaled $253.1 million as of December 31, 2023.
Headline financials
Revenue & EPS history
Enliven Therapeutics · Revenue · Quarterly
$440K
Forward guidance
Enliven Therapeutics is focused on advancing its clinical pipeline, with key milestones expected in 2024 for both ELVN-001 and ELVN-002, and has sufficient cash runway into early 2026.
Tailwinds
- ELVN-001 Phase 1 trial is on track.
- Initial proof of concept data for ELVN-001 expected in Q2 2024.
- FDA acceptance of ELVN-002 IND application.
- First patient dosing for ELVN-002 combination trial expected by mid-2024.
- Cash runway into early 2026.
Headwinds
- Significant net losses incurred since inception.
- Limited operating history.
- Risk of failing to demonstrate safety and efficacy of product candidates.
- Potential delays or difficulties in the enrollment or maintenance of patients in clinical trials.
- Reliance on third parties.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
-0.4%
Avg return
Earnings day
+2.4%
Avg return
5 days after
+7.4%
Avg return
30 days after
48%
11 / 23 earnings
Positive
+17.6%
Q2 2020
Best reaction
-22.5%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +4.3% | +3.4% | +35.1% | |
| Q3 2025 | -0.3% | +11.3% | -16.9% | |
| Q2 2025 | -0.8% | -1.1% | -0.1% | |
| Q1 2025 | +0.4% | +19.7% | +29.3% | |
| Q4 2024 | -3.5% | -7.7% | -14.6% | |
| Q3 2024 | -8.3% | -8.4% | -14.8% | |
| Q1 2024 | -2.0% | -5.9% | -10.1% | |
| Q4 2023 | -2.4% | +43.0% | +71.8% | |
| Q3 2023 | -9.3% | -12.4% | -4.5% | |
| Q2 2023 | -2.0% | -8.0% | -7.1% | |
| Q1 2023 | -2.4% | -0.3% | +8.8% | |
| Q4 2022 | +2.1% | +4.5% | +2.6% | |
| Q3 2022 | +0.4% | -5.5% | -1.3% | |
| Q2 2022 | +2.5% | -1.7% | -3.4% | |
| Q1 2022 | -6.1% | -11.5% | -12.2% | |
| Q4 2021 | +11.1% | +22.2% | -27.8% | |
| Q3 2021 | +0.8% | -3.8% | -20.2% | |
| Q2 2021 | +0.3% | -18.0% | -14.5% | |
| Q1 2021 | +12.8% | +15.8% | +27.3% | |
| Q4 2020 | -22.5% | -19.5% | -31.7% | |
| Q3 2020 | -3.4% | +13.9% | +57.0% | |
| Q2 2020 | +17.6% | +19.8% | +8.1% | |
| Q1 2020 | +1.1% | +4.4% | +108.5% | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro